Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results.

Takahashi K, Uchida K, Yoshimura N, Takahara S, Teraoka S, Teshima R, Cornu-Artis C, Kobayashi E.

Transplant Res. 2013 Jul 16;2(1):14. doi: 10.1186/2047-1440-2-14.

3.

Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.

Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H, Wang SS, Cantin B, Van Bakel A, Ewald G, Hirt S, Lehmkuhl H, Keogh A, Rinaldi M, Potena L, Zuckermann A, Dong G, Cornu-Artis C, Lopez P.

Am J Transplant. 2013 May;13(5):1203-16. doi: 10.1111/ajt.12181. Epub 2013 Feb 22.

5.

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.

Vítko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, Øyen O, Viljoen HG, Filiptsev P, Sadek S, Li Y, Cretin N, Budde K; RAD B201 Study Group.

Am J Transplant. 2005 Oct;5(10):2521-30. Erratum in: Am J Transplant. 2006 Jan;6(1):243.

6.

Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.

Lehmkuhl HB, Arizon J, Viganò M, Almenar L, Gerosa G, Maccherini M, Varnous S, Musumeci F, Hexham JM, Mange KC, Livi U; 2411 Study Investigators.

Transplantation. 2009 Jul 15;88(1):115-22. doi: 10.1097/TP.0b013e3181aacd22.

PMID:
19584690
7.

Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.

Cibrik D, Silva HT Jr, Vathsala A, Lackova E, Cornu-Artis C, Walker RG, Wang Z, Zibari GB, Shihab F, Kim YS.

Transplantation. 2013 Apr 15;95(7):933-42. doi: 10.1097/TP.0b013e3182848e03.

PMID:
23422495
8.

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.

Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, Kahan B, Sollinger H, Li Y, Cretin N, Tedesco H; B251 Study Group.

Transplantation. 2005 Jul 27;80(2):244-52.

PMID:
16041270
9.

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.

Vítko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Li Y, Jappe A, Cretin N; RAD B201 Study Group.

Transplantation. 2004 Nov 27;78(10):1532-40.

PMID:
15599319
10.

Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial.

Carmellini M, Garcia V, Wang Z, Vergara M, Russ G.

J Nephrol. 2015 Oct;28(5):633-9. doi: 10.1007/s40620-015-0180-6. Epub 2015 Feb 24.

PMID:
25708913
11.

Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.

Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS.

Transplantation. 2015 Jan;99(1):180-6. doi: 10.1097/TP.0000000000000225.

PMID:
24983307
12.

Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.

Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.

Transplant Proc. 2009 May;41(4):1152-5. doi: 10.1016/j.transproceed.2009.03.019.

PMID:
19460503
13.

Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients.

Uchida K, Hoshinaga K, Watarai Y, Goto N, Kusaka M, Sasaki H, Hirano M; A1202 PK Study Group.

Transplant Proc. 2014 Jun;46(5):1314-8. doi: 10.1016/j.transproceed.2014.01.010.

PMID:
24935294
14.

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F; ZEUS Study Investigators.

Lancet. 2011 Mar 5;377(9768):837-47. doi: 10.1016/S0140-6736(10)62318-5. Epub 2011 Feb 19. Erratum in: Lancet. 2012 Dec 8;380(9858):1994. Lancet. 2011 Jun 11;377(9782):2006. Wüthrich, Rudolf P [added].

PMID:
21334736
15.

Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.

Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF; RAD A2411 Study Investigators.

Transpl Infect Dis. 2010 Feb;12(1):23-30. doi: 10.1111/j.1399-3062.2009.00448.x. Epub 2009 Sep 9.

PMID:
19744284
16.

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study.

Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T; 156 Study Group.

Transplantation. 2004 Nov 15;78(9):1332-40.

PMID:
15548972
17.

Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

Tedesco Silva H Jr, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, Walker R, Wang Z, Zibari G, Kim YS.

Am J Transplant. 2010 Jun;10(6):1401-13. doi: 10.1111/j.1600-6143.2010.03129.x. Epub 2010 Apr 28.

18.

Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.

Albano L, Alamartine E, Toupance O, Moulin B, Merville P, Rerolle JP, Tetaz R, Moal MC, Kamar N, Legendre C, Quéré S, Di Giambattista F, Terpereau A, Dantal J.

Ann Transplant. 2012 Jan-Mar;17(1):58-67.

PMID:
22466910
19.

Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.

Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S.

Am J Transplant. 2017 May;17(5):1358-1369. doi: 10.1111/ajt.14090. Epub 2017 Jan 4.

PMID:
27775865
20.

Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.

Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Quéré S, Di Giambattista F, Cassuto E; RAD A2420 Study Group.

Transpl Int. 2010 Nov;23(11):1084-93. doi: 10.1111/j.1432-2277.2010.01094.x. Epub 2010 Aug 19. Erratum in: Transpl Int. 2012 Jan;25(1):138.

Supplemental Content

Support Center